Navigation Links
Valeant Announces Increase to Securities Repurchase Program
Date:5/28/2009

ALISO VIEJO, Calif., May 28 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) announced today that its board of directors has authorized the repurchase of an additional $300 million of its outstanding convertible debt or common stock under the securities repurchase program approved in October 2008. This repurchase authorization raises the aggregate repurchase authorization to $500 million from $200 million over a period ending May 2011. To date, the Company has repurchased $139 million in total of its convertible debt and its common stock out of the $500 million authorized under the securities repurchase program.

Under the securities repurchase program, the Company may repurchase its securities from time to time on the open market, in privately negotiated transactions pursuant to tender offers or otherwise, including pursuant to one or more trading plans, at times and in amounts as the Company deems appropriate. The amount of securities to be purchased and the timing of purchases may be subject to various factors, which may include the price of the securities, general market conditions, corporate and regulatory requirements and alternate investment opportunities. The repurchase program may be modified or discontinued at any time.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including, but not limited to, statements regarding the securities repurchase program. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to the market conditions, the Company's ability to execute purchases under the securities repurchase program and other risks and uncertainties as set forth under the caption "Risk Factors" in the Company's most recent annual or quarterly report filed with the SEC, which factors are incorporated herein by reference. Valeant wishes to caution the reader that these factors are among the factors that could cause actual results to differ materially from the expectations described in the forward-looking statements. Valeant also cautions the reader that undue reliance should not be placed on any of the forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this release or to reflect actual outcomes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002
    laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
6. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
7. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
8. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
9. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
10. Valeant to Acquire Polish Dermatology Company
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , ... February 24, 2017 , ... ... Charlevoix, once again hosted their Military Wedding Giveaway, with the winning couple announced ... Castle Farms with services generously donated from local vendors: A Matter of Taste, ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Club in Miami Beach to host its Swirl: Miami Wine Tasting Event on ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. Hamid ... sponsoring a raffle. Throughout the month of February, patients who visit Hamlin Dental Group ... for a dinner for two at the Cheesecake Factory. , Tickets are available ...
(Date:2/23/2017)... ... 23, 2017 , ... Dr. David Mahon leads Siena Dental, a comprehensive dental ... named a 2017 Top Patient Rated Henderson Dentist by Find Local Doctors ... local physicians and dentists who have earned high ratings and superior patient reviews from ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare ... for those in the fight against cancer, has produced a seminal study that ... HRA will release top-line findings in a webinar, Defining Compassionate Care Through the ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)... Feb. 23, 2017 Non-alcoholic steatohepataitis ... the various drugs being developed for the ... the drugs that are in various phases ... pipeline focuses on novel pharmacologic drugs & ... cell therapies, recombinant proteins and RNA-based therapeutics, ...
(Date:2/24/2017)... Medivir AB (Nasdaq Stockholm: MVIR) today announced ... Directors that will be submitted to the 2017 Annual ... the company,s three largest shareholders at the end of ... seat on the Nomination Committee, and the Chairman of ... was as follows:  Anders ...
Breaking Medicine Technology: